Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2877 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 05 Nov 2026, 03:15 UTC
2877
Studies in scope
industry-sponsored, all four open statuses
1383
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 46 Bristol 18 Manchester 17 Oxford 15 Birmingham 14
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca139 Merck Sharp & Dohme LLC98 Hoffmann-La Roche83 Novartis Pharmaceuticals72 Janssen Research & Development, LLC70 Clear sponsor filter
Site city
London46 Bristol18 Manchester17 Oxford15 Birmingham14
All 106 cities
Target enrolment
to

Trials with a site in London

46 of 2877 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
Eli Lilly and Company
Phase 3
2,115
Blackpool, Lancashire, London, Penzance, Romsey, West Kirby
2026-12
Recruiting
Eli Lilly and Company
Phase 2
606
Cheadle, Ely, Hounslow, London, Penzance, West Kirby
2026-08-07
Recruiting
Eli Lilly and Company
Phase 3
170
Hull, Liverpool, London
2026-07-08
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
London, Nottingham, Plymouth, Southampton
2026-04-17
Recruiting
Eli Lilly and Company
Phase 2
65
London, Salford
2026-04-14
Recruiting
Eli Lilly and Company
Phase 2
465
Chertsey, Doncaster, Eastbourne, Glasgow, London, Manchester, Milton Keynes, Southampton
2026-02-13
Recruiting
Eli Lilly and Company
Phase 3
1,000
Edinburgh, Exeter, Glasgow, London, Nottingham, Oxford, Penzance, Rotherham
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
900
Bristol, Glasgow, London, Newcastle, Penzance, Rotherham, Sheffield, York
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
150
Birmingham, Cambridge, Cardiff, Glasgow, London, Oxford, Southampton
2026-01-12
Recruiting
Eli Lilly and Company
Phase 3
800
Edinburgh, Huddersfield, London, Manchester, Plymouth, Worcester
2025-12-22
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Huddersfield, London, Manchester, Sheffield
2025-12-12
Recruiting
Eli Lilly and Company
Phase 3
1,205
London, Plymouth, Stoke-on-Trent, Swansea, West End
2025-10-31
Recruiting
Eli Lilly and Company
Phase 3
1,630
Bath, Leeds, London, Manchester, Torquay
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
1,100
Blackpool, Doncaster, Eastbourne, Glasgow, Hayle, Hounslow, London, Newquay
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
1,100
Blackpool, Chester, Eastbourne, Edinburgh, Glasgow, London, Manchester, Southampton
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
4,500
Aberdeen, Clifton, Enfield, Glasgow, Ipswich, Liverpool, London, Newcastle upon Tyne
2025-10-15
Recruiting
Eli Lilly and Company
Phase 1/2
68
Bristol, Leeds, Leicester, London
2025-07-30
Recruiting
Eli Lilly and Company
Phase 3
350
Bristol, Dundee, Exeter, London
2025-06-26
Recruiting
Eli Lilly and Company
Phase 3
700
Birmingham, East Sussex, Huddersfield, London, Manchester, Torquay
2025-03-27
Active, closed
Eli Lilly and Company
Phase 3
1,400
Bath, Birmingham, Blackpool, Edinburgh, London, Manchester, Motherwell, Plymouth
2024-10-24
Recruiting
Eli Lilly and Company
Phase 1
56
London, Sheffield, Southampton
2024-08-15
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
DrugPembrolizumab
Eli Lilly and Company
Phase 1
460
London, Manchester
2024-07-01
Recruiting
Eli Lilly and Company
Phase 3
300
Cambridge, Glagow, Leeds, Leicester, Liverpool, London, Newcastle upon Tyne, Sheffield
2024-06-03
Recruiting
Eli Lilly and Company
Phase 3
510
Bristol, Chelsea, Great Yarmouth, London, Newcastle upon Tyne, Stockport
2024-04-29
Recruiting
Eli Lilly and Company
Phase 3
90
Edinburgh, Headington, London, Manchester, Sheffield, Whitechapel
2024-03-13
Active, closed
Eli Lilly and Company
Phase 3
17,300
Blackpool, Bristol, Cheadle, Enfield, Glasgow, Hull, London, Newcastle upon Tyne
2024-03-05
Recruiting
Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
NCT05821959Sensorineural Hearing Loss, Bilateral
Eli Lilly and Company
Phase 3
48
London
2023-09-15
Active, closed
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugsDonanemab·Dexamethasone
Eli Lilly and Company
Phase 3
1,175
Bristol, Winchester, London, Guildford, Birmingham, Plymouth
2023-02-28
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugDonanemab
Eli Lilly and Company
Phase 3
1,500
Bath, Birmingham, Bristol, Chertsey, Crowborough, Guildford, London, Nottinghamshire
2022-10-10
Active, closed
Eli Lilly and Company
Phase 3
8,000
Colchester, East Kilbride, Glasgow, Edinburgh, Liverpool, London, Manchester, Northwood, Plymouth
2022-10-04
Active, closed
Eli Lilly and Company
Phase 1
260
London, Sutton
2022-05-11
Active, closed
Eli Lilly and Company
Phase 3
925
Blackburn, Colchester, London
2022-04-14
Active, closed
Eli Lilly and Company
Phase 3
152
London, Nottingham, Wolverhampton
2021-12-20
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
London, Oxford, Sheffield
2021-05-26
Active, closed
Eli Lilly and Company
Phase 3
996
Cambridge, London, Cardiff
2020-06-22
Active, closed
Eli Lilly and Company
Phase 3
1,736
Motherwell, London, Guildford, Birmingham
2020-06-19
Active, closed
Eli Lilly and Company
Phase 3
58
Bristol, Liverpool, London, Oxford, Sheffield
2020-02-12
Recruiting
Eli Lilly and Company
Phase 2
105
London, Manchester
2020-01-22
Active, closed
Eli Lilly and Company
Phase 3
30
Bristol, Cambridge, Liverpool, Newcastle upon Tyne, Southampton, London, Sheffield
2019-10-16
Active, closed
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
NCT03899792Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
DrugSelpercatinib
Eli Lilly and Company
Phase 1/2
36
London
2019-06-13
Recruiting
Eli Lilly and Company
Phase 3
190
Bristol, Liverpool, London, Oxford, Sheffield
2019-04-05
Active, closed
Eli Lilly and Company
Phase 3
1,058
Bury, London, Oxford
2018-07-18
Active, closed
Eli Lilly and Company
Phase 3
5,637
Truro, Chelmsford, London, Northwood, Blackpool, Preston, Boston, Central Middlesbrough
2017-07-12
Active, closed
Eli Lilly and Company
Phase 1/2
857
London
2017-05-02
Active, closed
Eli Lilly and Company
Phase 2
309
London, Manchester, Acton, Bebbington, Sutton
2016-05-19
Active, closed
Eli Lilly and Company
Phase 3
545
London, Chelsea, Nottingham
2015-05-06
Rows per page Showing 1–46 of 46
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 5 November 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,877 studies in total at the last sync on 05 Nov 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 46 of those studies with a site in London that also match the filters currently applied.

How many clinical trials are recruiting in London?

27 of the 46 studies on this page are recruiting new participants as of the 05 Nov 2026, 03:15 UTC sync. A further 1 have not yet opened recruitment, 18 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (London), 46 studies
PhaseStudiesRecruitingShare
Phase 3341973.9%
Phase 25410.9%
Phase 1438.7%
Phase 1/2316.5%

Most active sponsors

Lead sponsors with the most studies (London)
Lead sponsorStudiesRecruiting
Eli Lilly and Company4627
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.